Skip to main content

Von Willebrand Disease (VWD)

0
Pipeline Programs
2
Companies
10
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
4 programs
TAK-577N/A1 trial
VONVENDIPHASE_31 trial
Vonicog AlfaPHASE_31 trial
rVWFPHASE_35 trials
Active Trials
NCT06173024Available
NCT07129343Recruiting20Est. Nov 2027
NCT05582993Recruiting24Est. Apr 2030
+5 more trials
Hemab Therapeutics
Hemab TherapeuticsDenmark - Copenhagen
2 programs
Clinical outcomes of patients with VWD, Type 1N/A1 trial
HMB-002PHASE_1_21 trial
Active Trials
NCT06610201Recruiting200Est. Dec 2026
NCT06754852Recruiting108Est. Jul 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaVONVENDI
TakedaVonicog Alfa
TakedarVWF
TakedarVWF
TakedarVWF
TakedarVWF
Hemab TherapeuticsHMB-002
TakedarVWF
Hemab TherapeuticsClinical outcomes of patients with VWD, Type 1

Clinical Trials (10)

Total enrollment: 512 patients across 10 trials

A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)

Start: Oct 2025Est. completion: Nov 202720 patients
Phase 3Recruiting
NCT05582993TakedaVonicog Alfa

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Start: Nov 2024Est. completion: Apr 203024 patients
Phase 3Recruiting

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Start: Apr 2019Est. completion: Jan 202538 patients
Phase 3Completed

rVWF IN PROPHYLAXIS

Start: Nov 2017Est. completion: Jul 202029 patients
Phase 3Completed

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Start: Nov 2017Est. completion: Mar 202631 patients
Phase 3Recruiting

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)

Start: Nov 2011Est. completion: Feb 201449 patients
Phase 3Completed

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Start: Feb 2025Est. completion: Jul 2027108 patients
Phase 1/2Recruiting

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

N/AAvailable

An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

Start: Feb 2026Est. completion: May 203113 patients
N/ARecruiting
NCT06610201Hemab TherapeuticsClinical outcomes of patients with VWD, Type 1

A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Start: Aug 2024Est. completion: Dec 2026200 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

6 actively recruiting trials targeting 512 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.